New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
07:34 EDTINCYIncyte duration of response not an issue, says Jefferies
Jefferies says the shorter than expected duration of response for Incyte's '360 with ipilimumab is not an issue since the progression-free survival number is strong. Jefferies believes last night's data suggests that '360 offers up to three times the clinical benefit expected with ipilimumab alone. It maintains a Buy rating on Incyte shares with an $80 price target.
News For INCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 31, 2014
10:00 EDTINCYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
October 30, 2014
18:41 EDTINCYIncyte upgraded to Neutral from Sell at Goldman
Subscribe for More Information
13:35 EDTINCYIncyte price target raised to $80 from $69 at Piper Jaffray
Piper Jaffray raised its price target for Incyte shares to $80 saying Jakafi demand was strong in Q3. Piper keeps an Overweight rating on the stock.
07:11 EDTINCYIncyte reports Q3 EPS 33c, may not compare to consensus 0c
Reports Q3 revenue $198.15M, consensus $149.92M. The Company now expects that 2014 net product revenues from Jakafi will be in the range of $350 million to $360 million, an increase from the previous range of $330 million to $340 million.
October 21, 2014
07:54 EDTINCYLeerink a buyer of Alkermes, ImmunoGen, Incyte
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use